Company

From a CERN spin-off in Geneva to a product-driven MedTech company, Terapet develops next-generation imaging solutions that connect treatment planning with in vivo verification in radiation therapy and nuclear medicine. 

From high-energy physics to clinical practice

Terapet SA was founded in 2019 in Geneva, Switzerland, as a CERN spin-off with the ambition to bring advanced detector technologies from high-energy physics into clinical practice.

Built on a novel gamma-ray detection platform, Terapet develops next-generation imaging solutions designed to bridge the gap between treatment planning and in vivo verification. From the beginning, the company has focused on translating complex physics into clinically deployable systems that improve confidence, accuracy, and decision-making in radiation therapy and nuclear medicine.

Through collaborations with leading institutions such as CERN, Karolinska Institute, and Skandion Clinic, Terapet has rapidly evolved from early-stage innovation to a product-driven MedTech company. The development of Qualyscan® marked a key milestone, introducing a new approach to activity-based verification in particle therapy.

Today, Terapet operates at the intersection of nuclear imaging, particle therapy, and theranostics, working with hospitals, research centres, and industry partners worldwide to enable a shift from planned treatments to verified, data-driven care.

Key milestones

Foundation

CERN spin-off founded in Geneva

Award-winning startup recognised in multiple Swiss innovation competitions, including Swiss Bic of CERN Technologies, Venture Kick Stage I, II and III, FIT, FIF, Top 10 Life Science Venture Leaders by Venturelab, Top 10 in Swiss Innovation Challenge, Top 10 Rising Star MedTech, and Top 100 Swiss Startups in 2021, 2022, 2023 and 2024.

2019
Early traction

Seed round of CHF 3 M

Early financial traction through equity, awards and grants, supporting the transition from research-based innovation toward structured product development.

2020
R&D partnerships and clinical validation

Building scientific and clinical partnerships

Partnerships with CERN, Karolinska Institute and Skandion Clinic, supported by Innosuisse and the European Commission.

2021
Product & scale

Launch of Qualyscan®

Launch of Qualyscan® at PTCOG and completion of Series A of CHF 9 M, including equity, awards and grants.

2023
Clinical validation & expansion

Pre-clinical testing at Yonsei Cancer Center

Expansion of validation activities with pre-clinical testing in heavy ion therapy at Yonsei Cancer Center.

2024
Regulatory maturity

ISO 13485 certification

Strengthening of the quality and regulatory framework for clinical deployment.

2025
Adaptive therapy

TheraVivo project

TheraVivo project with RaySearch, Skandion Clinic and Uppsala University, focused on in vivo verification and adaptive particle therapy.

2026

Vision & Mission

Vision

To enable a new standard of precision medicine where diagnosis, treatment, and verification are seamlessly connected and every decision is driven by direct, measurable insight.

Mission

01

High-performance PET imaging

Deliver high-performance PET imaging for nuclear medicine and particle therapy.

02

In vivo treatment verification

Enable in vivo verification of radiation treatments through direct, measurable clinical insight.

03

Adaptive, data-driven therapy

Support the transition toward adaptive, data-driven therapy by connecting planning, delivery, and verification.

04

Scalable next-generation imaging

Expand access to next-generation imaging through scalable and cost-efficient solutions.

05

Clinical workflow integration

Our technologies are designed to integrate into clinical workflows while providing actionable information that improves treatment accuracy, accelerates drug development, and enhances patient outcomes.

Our Awards